Jianhui Li of Wanhuida Intellectual Property explains how China addresses the question of whether the features of an administration process limit a patented product and distinguish it from prior art
Tiejun Tang, Yuming Wang, and Jianhui Li of Wanhuida Intellectual Property discuss the evolving landscape in China around ‘offering for sale’, with reference to a high-profile Supreme People’s Court case involving a patented drug
Jianhui Li and Honghui Hu of Wanhuida Intellectual Property discuss the antitrust scrutiny of China’s Supreme People’s Court in a patent infringement appeal concerning reverse payment settlement agreement
Xiaohui Wu, Yuming Wang and Jianhui Li of Wanhuida Intellectual Property discuss the Supreme People’s Court’s first decision in parallel civil and administrative proceedings involving a chiral drug patent
